Basic Information
| LncRNA/CircRNA Name | LINC02595 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qRT-PCR, Western blot, Microarray |
| Sample | CRC tissues, cell lines (SW620, HT29, HCT116, RKO, Caco-2, and SW480),blood |
| Expression Pattern | up-regulated |
| Function Description | LINC02595 promoted BCL2-like 1 (BCL2L1) expression through miR-203b-3p sponging. Our research demonstrated that LINC02595 is an oncogene in CRC and established the presence of a LINC02595-miR-203b-BCL2L1 axis in CRC |
| Pubmed ID | 32064615 |
| Year | 2020 |
| Title | LINC02595 promotes tumor progression in colorectal cancer by inhibiting miR-203b-3p activity and facilitating BCL2L1 expression |
External Links
| Links for LINC02595 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |